Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells

    Research output: Contribution to journalArticleScientificpeer-review

    Abstract

    "Background. Recent data indicate a role for angiogenesis in hematologic malignancies. In addition to promoting new vessel growth in the bone marrow microenvironment, angiogenic factors are regulators of both hematopoietic and leukemic cells. Activation of vascular endothelial growth factor receptor 3 (VEGFR-3) and Tiel tyrosine kinase receptor are known to promote leukemia cell survival. The details of this complex angiogenesis-related interaction are still uncertain. Procedure. We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods. Results. Vascular endothelial growth factor receptor 3 expression was found in 15% of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs. Tiel protein expression was found in 11% of the samples, all of which were from adult AML patients. Conclusions. Our findings suggest that there are angiogenesis-related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias. Pediatr Blood Cancer 2007;48:387-392. (c) 2006 Wiley-Liss, Inc."
    Original languageEnglish
    JournalPediatric Blood & Cancer
    Volume48
    Issue number4
    Pages (from-to)387-392
    Number of pages6
    ISSN1545-5009
    DOIs
    Publication statusPublished - 2007
    MoE publication typeA1 Journal article-refereed

    Fields of Science

    • 3121 Internal medicine
    • 3123 Gynaecology and paediatrics
    • 3122 Cancers

    Cite this

    @article{99f0e912707246908d5650605f41da6b,
    title = "Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells",
    abstract = "{"}Background. Recent data indicate a role for angiogenesis in hematologic malignancies. In addition to promoting new vessel growth in the bone marrow microenvironment, angiogenic factors are regulators of both hematopoietic and leukemic cells. Activation of vascular endothelial growth factor receptor 3 (VEGFR-3) and Tiel tyrosine kinase receptor are known to promote leukemia cell survival. The details of this complex angiogenesis-related interaction are still uncertain. Procedure. We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods. Results. Vascular endothelial growth factor receptor 3 expression was found in 15{\%} of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs. Tiel protein expression was found in 11{\%} of the samples, all of which were from adult AML patients. Conclusions. Our findings suggest that there are angiogenesis-related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias. Pediatr Blood Cancer 2007;48:387-392. (c) 2006 Wiley-Liss, Inc.{"}",
    keywords = "3121 Internal medicine, 3123 Gynaecology and paediatrics, 3122 Cancers",
    author = "Sanna-Maria Kivivuori and Sanna Siitonen and Kimmo Porkka and Kim Vettenranta and Riitta Alitalo and Saarinen-Pihkala, {Ulla M.}",
    year = "2007",
    doi = "10.1002/pbc.20857",
    language = "English",
    volume = "48",
    pages = "387--392",
    journal = "Pediatric Blood & Cancer",
    issn = "1545-5009",
    publisher = "Wiley",
    number = "4",

    }

    TY - JOUR

    T1 - Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells

    AU - Kivivuori, Sanna-Maria

    AU - Siitonen, Sanna

    AU - Porkka, Kimmo

    AU - Vettenranta, Kim

    AU - Alitalo, Riitta

    AU - Saarinen-Pihkala, Ulla M.

    PY - 2007

    Y1 - 2007

    N2 - "Background. Recent data indicate a role for angiogenesis in hematologic malignancies. In addition to promoting new vessel growth in the bone marrow microenvironment, angiogenic factors are regulators of both hematopoietic and leukemic cells. Activation of vascular endothelial growth factor receptor 3 (VEGFR-3) and Tiel tyrosine kinase receptor are known to promote leukemia cell survival. The details of this complex angiogenesis-related interaction are still uncertain. Procedure. We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods. Results. Vascular endothelial growth factor receptor 3 expression was found in 15% of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs. Tiel protein expression was found in 11% of the samples, all of which were from adult AML patients. Conclusions. Our findings suggest that there are angiogenesis-related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias. Pediatr Blood Cancer 2007;48:387-392. (c) 2006 Wiley-Liss, Inc."

    AB - "Background. Recent data indicate a role for angiogenesis in hematologic malignancies. In addition to promoting new vessel growth in the bone marrow microenvironment, angiogenic factors are regulators of both hematopoietic and leukemic cells. Activation of vascular endothelial growth factor receptor 3 (VEGFR-3) and Tiel tyrosine kinase receptor are known to promote leukemia cell survival. The details of this complex angiogenesis-related interaction are still uncertain. Procedure. We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods. Results. Vascular endothelial growth factor receptor 3 expression was found in 15% of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs. Tiel protein expression was found in 11% of the samples, all of which were from adult AML patients. Conclusions. Our findings suggest that there are angiogenesis-related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias. Pediatr Blood Cancer 2007;48:387-392. (c) 2006 Wiley-Liss, Inc."

    KW - 3121 Internal medicine

    KW - 3123 Gynaecology and paediatrics

    KW - 3122 Cancers

    U2 - 10.1002/pbc.20857

    DO - 10.1002/pbc.20857

    M3 - Article

    VL - 48

    SP - 387

    EP - 392

    JO - Pediatric Blood & Cancer

    JF - Pediatric Blood & Cancer

    SN - 1545-5009

    IS - 4

    ER -